207 related articles for article (PubMed ID: 23656525)
1. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.
von Haehling S
Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525
[TBL] [Abstract][Full Text] [Related]
2. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
3. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
[TBL] [Abstract][Full Text] [Related]
5. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
[TBL] [Abstract][Full Text] [Related]
6. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
[TBL] [Abstract][Full Text] [Related]
7. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
[TBL] [Abstract][Full Text] [Related]
8. [Indications and potential benefits of implantable automatic defibrillator endowed with biventricular pacing].
Ansalone G; Ricci R; Cacciatore G; Santini M
Ital Heart J Suppl; 2001 Dec; 2(12):1308-14. PubMed ID: 11838353
[TBL] [Abstract][Full Text] [Related]
9. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
10. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
[TBL] [Abstract][Full Text] [Related]
11. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
Wilkoff BL;
Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
[TBL] [Abstract][Full Text] [Related]
13. [Organ-protection therapy. A new therapeutic approach for acute heart failure?].
Chivite D; Formiga F; Corbella X
Med Clin (Barc); 2014 Mar; 142 Suppl 1():66-71. PubMed ID: 24930087
[TBL] [Abstract][Full Text] [Related]
14. The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
Ruwald AC; Pietrasik G; Goldenberg I; Kutyifa V; Daubert JP; Ruwald MH; Jons C; McNitt S; Wang P; Zareba W; Moss AJ
J Am Coll Cardiol; 2014 Apr; 63(12):1190-1197. PubMed ID: 24333490
[TBL] [Abstract][Full Text] [Related]
15. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
Schmieder RE; Mitrovic V; Hengstenberg C
Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
[TBL] [Abstract][Full Text] [Related]
17. Serelaxin : a potential new drug for the treatment of acute heart failure.
Neverova N; Teerlink JR
Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
[TBL] [Abstract][Full Text] [Related]
18. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
19. Effects of Serelaxin in Patients with Acute Heart Failure.
Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
[TBL] [Abstract][Full Text] [Related]
20. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
